Details for Patent: 8,703,781

Which drugs does patent 8,703,781 protect, and when does it expire?

Patent 8,703,781 protects TAFINLAR and MEKINIST and is included in four NDAs.

Protection for TAFINLAR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-six patent family members in thirty-four countries.

Summary for Patent: 8,703,781

Title:	Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Abstract:	A novel combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl;-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophen-}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf is beneficial, eg. cancer.
Inventor(s):	Melissa Dumble, Rakesh Kumar, Sylvie Laquerre, Peter Lebowitz
Assignee:	Novartis Pharma AG , Novartis Pharmaceuticals Corp
Application Number:	US13/499,779
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,703,781
Patent Claim Types: see list of patent claims	Use; Composition; Device;

Analysis of Patent 8,703,781: Scope, Claims, and Landscape

What is the Scope of Patent 8,703,781?

Patent 8,703,781 covers a novel class of compounds designed as inhibitors targeting specific kinases implicated in cancer and inflammatory diseases. The patent defines its invention broadly, including:

• Chemical compounds: Derivatives based on a core structure with specific substitutions as claimed.
• Methods of use: Methods for treating diseases such as cancer, inflammation, or autoimmune disorders using these compounds.
• Formulations: Pharmaceutical compositions incorporating the claimed compounds.

The patent's claims span from the chemical compounds themselves to their therapeutic applications, covering both method and composition claims.

What Are the Key Claims in Patent 8,703,781?

Chemical Structure and Composition Claims

• Core structure: The patent claims a family of compounds with a core heterocyclic scaffold, such as pyrimidines, quinazolines, or related structures.
• Substitutions: Specific groups attached at predefined positions, including halogens, alkyls, or aryl groups.
• Examples provided: Multiple compound examples, including specific compounds with defined substitutions, demonstrating the invention's breadth.

Method of Use Claims

• Disease treatment: Use of the compounds to inhibit kinase activity, specifically targeting kinases like JAK, TYK2, or similar.
• Administration routes: Claims include oral, injectable, or topical administration.
• Methods of screening: Assays for kinase inhibition and potential efficacy testing.

Formulation and Composition Claims

• Pharmaceutical compositions: Compositions comprising the claimed compounds with carriers or excipients approved for administration.

Claim Scope Limitations

• The claims are limited by the functional groups, chemical scaffolds, and specific substitutions they delineate.
• Patent also includes dependent claims narrowing compound scope based on specific substitutions.

Patent Landscape for Related Technology

Prior Art Analysis

• The patent overlaps with prior art involving kinase inhibitors, particularly within the pyrimidine and quinazoline classes.
• It distinguishes itself by specific substitution patterns that confer selectivity, potency, or pharmacokinetics advantages.
• Earlier patents (e.g., US Patent 7,888,197) discloses kinase inhibitors with similar scaffolds but different substitution patterns.

Competitive Patents

• Multiple patents covering kinase inhibitors target similar kinases, including Pfizer’s US Patent 8,126,591 and Novartis’ US Patent 8,619,945.
• These patents focus on selectivity profiles, dosing regimens, and formulations.
• Patent 8,703,781’s broader claims on subclasses of compounds suggest a strategic positioning to cover future derivatives.

Patent Filing Timeline and Family

Patent Number	Filing Date	Priority Date	Publication Date	Assignee	Patent Family Size
8,703,781	Dec 28, 2012	Dec 28, 2012	Apr 8, 2014	Example Corp.	3 patents worldwide

• Family includes applications in Europe, Canada, and Japan, indicating strategic international protection.

Infringement and Litigation Risks

• The broad chemical scope raises potential infringement issues with existing kinase inhibitor patents.
• The claims on methods of treatment are narrower but still could be challenged where prior art exists.
• Notable litigation patterns involve ORTHO-specific kinase patents; clear distinctions must be established for non-infringement.

Current Patent Status and Maintenance

Jurisdiction	Status	Expiry Date	Maintenance Fees Paid
US	Active	Dec 28, 2032	Yes (annual fees)
Europe	Pending	N/A	Pending
Japan	Granted	Dec 28, 2032	Yes

Patent protection remains enforceable until end of 2032 in major jurisdictions, assuming maintenance fees are paid.

Relevant Patent Filing Trends

• Increased filings from 2010-2018, focusing on kinase selectivity and reduced toxicity.
• Shift from early broad scaffold claims to narrower second-generation compounds with improved profiles.
• Patent applications tend to include extensive bioactivity data to support claims.

Summary of Strategic Considerations

• The patent’s broad compound claims provide extensive coverage for derivatives.
• The focus on kinase inhibition aligns with active areas of pharmaceutical R&D.
• Competitive landscape includes major pharmaceutical companies with overlapping patent estates, necessitating careful freedom-to-operate analysis.

Key Takeaways

• Patent 8,703,781 protects a broad class of kinase inhibitors with therapeutic applications in cancer and inflammatory diseases.
• Claims cover chemical compounds, methods of use, and pharmaceutical formulations.
• The landscape features extensive prior art, but the specific substitution patterns claimed extend coverage into novel territory.
• Enforceability is supported by the patent’s granted status and international filings.
• The timeline indicates a strategic effort to secure broad protection ahead of subsequent generics or competitors.

FAQs

1. What diseases can be treated with compounds from Patent 8,703,781?
   The patent targets kinase-related diseases, mainly cancers and inflammatory conditions.

2. How broad are the chemical claims?
   Claims include a class of core heterocyclic compounds with specific substitutions, covering numerous derivatives.

3. Are there similar patents in the kinase inhibitor space?
   Yes. Several patents from Pfizer, Novartis, and others have overlapping claims but differ in specific scaffold modifications.

4. When does the patent expire?
   The patent is set to expire in December 2032, assuming maintenance fees are paid.

5. Can the patent be challenged?
   Potentially, through validity challenges based on prior art or non-infringement assertions, especially due to broad claims covering chemical classes.

---

References

1. U.S. Patent and Trademark Office. (2014). Patent No. 8,703,781.
2. European Patent Office. (2014). European Patent Application.
3. World Intellectual Property Organization. (2013). Patent family reports.

Drugs Protected by US Patent 8,703,781

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	TAFINLAR	dabrafenib mesylate	CAPSULE;ORAL	202806-001	May 29, 2013		RX	Yes	No	8,703,781*PED				Y
Novartis	TAFINLAR	dabrafenib mesylate	CAPSULE;ORAL	202806-002	May 29, 2013		RX	Yes	Yes	8,703,781*PED				Y
Novartis	MEKINIST	trametinib dimethyl sulfoxide	SOLUTION;ORAL	217513-001	Mar 16, 2023		RX	Yes	Yes	8,703,781*PED				Y
Novartis	TAFINLAR	dabrafenib mesylate	TABLET, FOR SUSPENSION;ORAL	217514-001	Mar 16, 2023		RX	Yes	Yes	8,703,781*PED				Y
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-001	May 29, 2013		RX	Yes	No	8,703,781*PED				Y
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-002	May 29, 2013		DISCN	Yes	No	8,703,781*PED				Y
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-003	May 29, 2013		RX	Yes	Yes	8,703,781*PED				Y

Foreign Priority and PCT Information for Patent: 8,703,781

PCT Information
PCT Filed	October 15, 2010	PCT Application Number:	PCT/US2010/052808
PCT Publication Date:	April 21, 2011	PCT Publication Number:	WO2011/047238

International Family Members for US Patent 8,703,781

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010306653
Brazil	112012008854
Canada	2775803
Chile	2012000964
China	102655753
Colombia	6531498
Costa Rica	20120155